You are here

Article Text

Article menu
Download PDFPDF
DTB select
Donanemab in early symptomatic Alzheimer’s disease

Abstract

Overview of: Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023;330:512-27

  • Drug-Related Side Effects and Adverse Reactions
  • Health Care Quality, Access, and Evaluation

https://doi.org/10.1136/dtb.2024.000020

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors DTB Team.

    • Provenance and peer review Commissioned; internally peer reviewed.